| Drug General Information |
| Drug ID |
D0XF5P
|
| Former ID |
DNC009136
|
| Drug Name |
(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C15H17NO
|
| Canonical SMILES |
C1CNCC1OCC2=CC3=CC=CC=C3C=C2
|
| InChI |
1S/C15H17NO/c1-2-4-14-9-12(5-6-13(14)3-1)11-17-15-7-8-16-10-15/h1-6,9,15-16H,7-8,10-11H2/t15-/m1/s1
|
| InChIKey |
IQZVBBALTJFFCB-OAHLLOKOSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Sodium-dependent noradrenaline transporter |
Target Info |
Inhibitor |
[1]
|
|---|
| Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
| Sodium-dependent dopamine transporter |
Target Info |
Inhibitor |
[1]
|
| Potassium voltage-gated channel subfamily H member 2 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Serotonergic synapsehsa04728:Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholism
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesisP04373:5HT1 type receptor mediated signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
5HT3 type receptor mediated signaling pathway
|
|
5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Parkinson disease
|
|
Dopamine receptor mediated signaling pathway
|
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transportersR-HSA-1296072:Voltage gated Potassium channels
|
|
WikiPathways
|
Monoamine Transport
|
|
NRF2 pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
Synaptic Vesicle Pathway
|
|
Serotonin Transporter ActivityWP727:Monoamine Transport
|
|
Dopaminergic Neurogenesis
|
|
Parkinsons Disease Pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
|
Neurotransmitter Clearance In The Synaptic CleftWP706:SIDS Susceptibility Pathways
|
|
Hematopoietic Stem Cell Differentiation
|
|
Potassium Channels
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. Epub 2009 Feb 20.Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. |
|---|
